Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Proteon Therapeutics (PRTO) PT Lowered to $1 at Baird
March 28, 2019 11:19 AM EDTBaird analyst Michael Ulz lowered the price target on Proteon Therapeutics (NASDAQ: PRTO) to $1.00 (from $3.00) while maintaining a Neutral rating.
Ulz commented, "This morning, Proteon announced disappointing top-line results from the Phase 3 PATENCY-2 study of vonapanitase, indicating the co-primary endpoints of fistula use for... More
Maxim Group Downgrades Proteon Therapeutics (PRTO) to Hold
March 28, 2019 10:42 AM EDTMaxim Group analyst Jason McCarthy downgraded Proteon Therapeutics (NASDAQ: PRTO) from Buy to Hold after second phase 3 study of vonapanitase failed to reach statistical significance on both co-primary endpoints.
For an analyst ratings summary and ratings history on Proteon Therapeutics... More
Proteon Therapeutics (PRTO) to Resume Trading at 8:30 am ET
March 28, 2019 8:08 AM EDTProteon Therapeutics (NASDAQ: PRTO) to Resume Trading at 8:30 am ET
